[
  {
    "ts": "2025-11-14T00:37:00+00:00",
    "headline": "Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs",
    "summary": "Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners with Eli Lilly and Novo Nordisk…”. The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 m",
    "url": "https://finance.yahoo.com/news/mangoceuticals-provides-clarification-launch-branded-003700946.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6159aeb4-4799-337e-b343-f892b6303057",
      "content": {
        "id": "6159aeb4-4799-337e-b343-f892b6303057",
        "contentType": "STORY",
        "title": "Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs",
        "description": "",
        "summary": "Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners with Eli Lilly and Novo Nordisk…”. The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 m",
        "pubDate": "2025-11-14T00:37:00Z",
        "displayTime": "2025-11-14T00:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/94775c7523023e222b2a19fc37cc02ca",
          "originalWidth": 8000,
          "originalHeight": 4500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XnuNJ9Qe6ko.i5UiATBWRA--~B/aD00NTAwO3c9ODAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/94775c7523023e222b2a19fc37cc02ca.cf.webp",
              "width": 8000,
              "height": 4500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Yet6sa3uxTjLL1d634T49w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/94775c7523023e222b2a19fc37cc02ca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mangoceuticals-provides-clarification-launch-branded-003700946.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mangoceuticals-provides-clarification-launch-branded-003700946.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MGRX"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T06:15:00+00:00",
    "headline": "Netflix’s Stock Split Is Almost Here. Eli Lilly Could Be Next.",
    "summary": "The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.",
    "url": "https://www.barrons.com/articles/stock-split-netflix-eli-lilly-a586f249?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "b5559cb6-8619-32fb-8c93-df686d8c3da9",
      "content": {
        "id": "b5559cb6-8619-32fb-8c93-df686d8c3da9",
        "contentType": "STORY",
        "title": "Netflix’s Stock Split Is Almost Here. Eli Lilly Could Be Next.",
        "description": "",
        "summary": "The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.",
        "pubDate": "2025-11-14T06:15:00Z",
        "displayTime": "2025-11-14T06:15:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b5559cb6-8619-32fb-8c93-df686d8c3da9/netflix%E2%80%99s-stock-split-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/365ba1362c97d42416b3158eac8a1797",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GICue7yKKdDoZeWd0HbwjQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/365ba1362c97d42416b3158eac8a1797.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AyMkZ6h2u8WMtBUX0EK4Iw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/365ba1362c97d42416b3158eac8a1797.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-split-netflix-eli-lilly-a586f249?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NFLX"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T08:00:00+00:00",
    "headline": "Medicxi Announces €500 Million Fund V",
    "summary": "Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi's pioneering asset-centric investment model.",
    "url": "https://finance.yahoo.com/news/medicxi-announces-500-million-fund-080000306.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "15a49308-e051-3ea0-ba9b-c9e499a6d194",
      "content": {
        "id": "15a49308-e051-3ea0-ba9b-c9e499a6d194",
        "contentType": "STORY",
        "title": "Medicxi Announces €500 Million Fund V",
        "description": "",
        "summary": "Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi's pioneering asset-centric investment model.",
        "pubDate": "2025-11-14T08:00:00Z",
        "displayTime": "2025-11-14T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c75b9bd6cf5986d3134896c7f127f3e2",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VuDuVP_.IF9RUa0p9thvqw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c75b9bd6cf5986d3134896c7f127f3e2.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CZeTaFdpoqArgqmV00I8Gg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c75b9bd6cf5986d3134896c7f127f3e2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/medicxi-announces-500-million-fund-080000306.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/medicxi-announces-500-million-fund-080000306.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABVX.PA"
            },
            {
              "symbol": "PCVX"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GMAB.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T11:15:00+00:00",
    "headline": "Why Is Everyone Talking About Novo Nordisk Stock?",
    "summary": "There is hardly a dull moment for the drugmaker these days.",
    "url": "https://www.fool.com/investing/2025/11/14/why-is-everyone-talking-about-novo-nordisk-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e52c5425-ada0-3243-a470-27eb124e82c8",
      "content": {
        "id": "e52c5425-ada0-3243-a470-27eb124e82c8",
        "contentType": "STORY",
        "title": "Why Is Everyone Talking About Novo Nordisk Stock?",
        "description": "",
        "summary": "There is hardly a dull moment for the drugmaker these days.",
        "pubDate": "2025-11-14T11:15:00Z",
        "displayTime": "2025-11-14T11:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ada7dbe0c44490944adaf52154be74bc",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Person sitting at a desk looking at two monitors displaying stock charts.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9KqCntdyogqdrXiCISkQPQ--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/ada7dbe0c44490944adaf52154be74bc.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3ic3He1fwJebVPIz2j5tOA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ada7dbe0c44490944adaf52154be74bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/14/why-is-everyone-talking-about-novo-nordisk-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-everyone-talking-novo-nordisk-111500612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T13:00:41+00:00",
    "headline": "Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim",
    "summary": "The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.",
    "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-and-novo-nordisk-disown-mangoceuticals-glp-1ra-partnership-claim/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "7af73c08-09de-3221-acf5-d305e3d973d7",
      "content": {
        "id": "7af73c08-09de-3221-acf5-d305e3d973d7",
        "contentType": "STORY",
        "title": "Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim",
        "description": "",
        "summary": "The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.",
        "pubDate": "2025-11-14T13:00:41Z",
        "displayTime": "2025-11-14T13:00:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/adcf11295754199b76bf5e0a8d4bb683",
          "originalWidth": 1000,
          "originalHeight": 444,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/coUAeaSseFvlAsf_Euc_pw--~B/aD00NDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/adcf11295754199b76bf5e0a8d4bb683.cf.webp",
              "width": 1000,
              "height": 444,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sMVWuvArsWHIbkAt20.wDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/adcf11295754199b76bf5e0a8d4bb683.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-and-novo-nordisk-disown-mangoceuticals-glp-1ra-partnership-claim/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-disown-130041879.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MGRX"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T12:59:00+00:00",
    "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
    "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
    "url": "https://finance.yahoo.com/news/pharma-etfs-spotlight-following-robust-125900300.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "10fc0cfd-b499-32b5-907f-5817647b3297",
      "content": {
        "id": "10fc0cfd-b499-32b5-907f-5817647b3297",
        "contentType": "STORY",
        "title": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
        "description": "",
        "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
        "pubDate": "2025-11-14T12:59:00Z",
        "displayTime": "2025-11-14T12:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/780f3ed4ed0b380d687c52a84b4582b8",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F9Duz3IXY6vI3GQX0iFRbg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/780f3ed4ed0b380d687c52a84b4582b8.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jvXjFQvI33DlpnQwQb.s8g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/780f3ed4ed0b380d687c52a84b4582b8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharma-etfs-spotlight-following-robust-125900300.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-etfs-spotlight-following-robust-125900300.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PJP"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "XPH"
            },
            {
              "symbol": "FTXH"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T12:37:00+00:00",
    "headline": "Zacks Investment Ideas feature highlights: IWM, CoreWeave, Astera Labs, Nebius, Expand Energy, Eli Lilly and Nvidia",
    "summary": "Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end positioning.",
    "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-123700372.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "510245e2-6819-35ac-92d0-c0d25fbac723",
      "content": {
        "id": "510245e2-6819-35ac-92d0-c0d25fbac723",
        "contentType": "STORY",
        "title": "Zacks Investment Ideas feature highlights: IWM, CoreWeave, Astera Labs, Nebius, Expand Energy, Eli Lilly and Nvidia",
        "description": "",
        "summary": "Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end positioning.",
        "pubDate": "2025-11-14T12:37:00Z",
        "displayTime": "2025-11-14T12:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-123700372.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-123700372.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "IWM"
            },
            {
              "symbol": "ALAB"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "CRWV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T15:53:50+00:00",
    "headline": "Novo Chairman Blames Board Dropout on Former Employer Pfizer",
    "summary": "The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.”  “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said.  Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.",
    "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "33199485-1b91-3453-ad37-b168daa959a1",
      "content": {
        "id": "33199485-1b91-3453-ad37-b168daa959a1",
        "contentType": "STORY",
        "title": "Novo Chairman Blames Board Dropout on Former Employer Pfizer",
        "description": "",
        "summary": "The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.”  “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said.  Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.",
        "pubDate": "2025-11-14T15:53:50Z",
        "displayTime": "2025-11-14T15:53:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74",
          "originalWidth": 1600,
          "originalHeight": 1067,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yyImDYGgGcKqsHHca7ayeQ--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74.cf.webp",
              "width": 1600,
              "height": 1067,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s_i5swtQx0TdQo8H5RNH5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T13:53:00+00:00",
    "headline": "Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?",
    "summary": "Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.",
    "url": "https://finance.yahoo.com/news/lillys-next-gen-obesity-drugs-135300254.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e47da764-220b-3389-a0ed-62f552859d67",
      "content": {
        "id": "e47da764-220b-3389-a0ed-62f552859d67",
        "contentType": "STORY",
        "title": "Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?",
        "description": "",
        "summary": "Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.",
        "pubDate": "2025-11-14T13:53:00Z",
        "displayTime": "2025-11-14T13:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-next-gen-obesity-drugs-135300254.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-next-gen-obesity-drugs-135300254.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]